FDA clears QIAstat-Dx bloodstream infection panel
Aug. 11, 2026—The FDA has cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Proscia gets new clearance for Concentriq AP-Dx
Aug. 10, 2026—Proscia received a new FDA 510(k) clearance for the Concentriq AP-Dx, a digital pathology platform for primary diagnosis.
Roche expands cyclospora testing portfolio in U.S.
Aug. 7, 2026—Roche, in collaboration with subsidiary Tib Molbiol, released two research PCR testing options for labs to address the public health impact of the Cyclospora cayetanensis parasite.
Epredia adds BlockTracker, SlideTracker to portfolio
Aug. 6, 2026—Epredia announced an agreement with Canada-based manufacturer Lab Improvements to bring automated archiving to U.S. pathology labs, adding Lab Improvements’ BlockTracker and SlideTracker to its product portfolio.
Roche gets FDA clearance for Cobas BV/CV assay
July 29, 2026–Roche received FDA 510(k) clearance for its Cobas BV/CV assay.
Beckman Coulter launches DxU 1800 automated urinalysis solution
July 29, 2026—Beckman Coulter Diagnostics has launched in the U.S. its DxU 1800 system, a fully automated urinalysis solution that combines the new DxU 1800c chemistry analyzer with a DxU Iris microscopy analyzer.
Waters launches Xevo TQ Absolute XR IVD mass spectrometer
July 28, 2026—Waters Corp. launched the Xevo TQ Absolute XR IVD mass spectrometer, expanding its MassTrak IVD system portfolio of LC-MS/MS systems.
Hardy Diagnostics showcases rapid lateral flow assays to combat AMR
July 28, 2026—Antimicrobial resistance (AMR) remains one of the most significant challenges facing health care today.
Werfen hosts education event on anticoagulation management
July 28, 2026—Werfen is hosting an education event on Wednesday, July 29, titled “Leading Change in Anticoagulation Management: Anti-Xa for Unfractionated Heparin Monitoring Across Lab, Pharmacy and Clinical Teams.”
ZeptoMetrix molecular quality controls on NATtrol swabs
July 28, 2026—Beyond our traditional liquid format, ZeptoMetrix introduces molecular quality controls on swabs.